Association between elevated brain amyloid and subsequent cognitive decline among cognitively normal persons

JAMA - Journal of the American Medical Association

Volumn 317, Issue 22, 2017, Pages 2305-2316

  Donohue, Michael C ^a   Sperling, Reisa A ^b,c   Petersen, Ronald ^d   Sun, Chung Kai ^a   Weiner, Michael ^e,f   Aisen, Paul S ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d MAYO CLINIC   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; AMYLOID BETA PROTEIN; BIOLOGICAL MARKER;

AGED; ARTICLE; CANADA; CEREBROSPINAL FLUID ANALYSIS; COGNITION; COGNITIVE DECLINE; COHORT ANALYSIS; CONTROLLED STUDY; EXPLORATORY RESEARCH; FEMALE; HUMAN; INFORMED CONSENT; LONGITUDINAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SCORING SYSTEM; UNITED STATES; ALZHEIMER DISEASE; BRAIN; CEREBROSPINAL FLUID; DIAGNOSTIC IMAGING; FOLLOW UP; MENTAL HEALTH; METABOLISM; POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY; RECALL; TIME FACTOR;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BIOMARKERS; BRAIN; CANADA; COGNITION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MENTAL RECALL; MENTAL STATUS SCHEDULE; POSITRON EMISSION TOMOGRAPHY COMPUTED TOMOGRAPHY; TIME FACTORS; UNITED STATES;

EID: 85020863360     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2017.6669     Document Type: Article

References (29)

1. Dubois B, Albert M L. Amnestic MCI or prodromal Alzheimer's disease? Lancet Neurol. 2004;3(4): 246-248.
2. Rowe CC, Ellis KA, Rimajova M, et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging. 2010;31(8):1275-1283.
3. Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7(3): 280-292.
4. Braak H, Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging. 1997;18(4):351-357.
5. Davies L, Wolska B, Hilbich C, et al. A4 amyloid protein deposition and the diagnosis of Alzheimer's disease. Neurology. 1988;38(11):1688-1693.
6. Vos SJ, Xiong C, Visser PJ, et al. Preclinical Alzheimer's disease and its outcome. Lancet Neurol. 2013;12(10):957-965.
7. Jack CR Jr, Therneau TM, Wiste HJ, et al. Transition rates between amyloid and neurodegeneration biomarker states and to dementia. Lancet Neurol. 2016;15(1):56-64.
8. Insel PS, Donohue MC, Mackin RS, et al. Cognitive and functional changes associated with Aβ pathology and the progression to mild cognitive impairment. Neurobiol Aging. 2016;48:172-181.
9. Sperling RA, Rentz DM, Johnson KA, et al. The A4 study: stopping AD before symptoms begin? Sci Transl Med. 2014;6(228):228.
10. Weiner M W, Veitch DP, Aisen PS, et al. Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014. Alzheimers Dement. 2015;11(7): 865-884.
11. Landau SM, Breault C, Joshi AD, et al. Amyloid-β imaging with Pittsburgh compound B and florbetapir. J Nucl Med. 2013;54(1):70-77.
12. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state": A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189-198.
13. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993; 43(11):2412-2414.
14. Wechsler D. WMS-R:Wechsler Memory Scale-Revised: Manual. San Antonio, TX: Psychological Corporation; 1987.
15. Donohue MC, Sperling RA, Salmon DP, et al. The preclinical Alzheimer cognitive composite. JAMA Neurol. 2014;71(8):961-970.
16. Shaw LM, Vanderstichele H, Knapik-Czajka M, et al. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol. 2009;65(4):403-413.
17. Dale AM, Fischl B, Sereno MI. Cortical surface-based analysis I: segmentation and surface reconstruction. Neuroimage. 1999;9(2):179-194.
18. Reitan RM, Wolfson D. The Halstead-Reitan Neuropsychological Test Battery: Theory and Clinical Interpretation. 2nd ed. Tucson, AZ: Neuropsychology Press; 1993.
19. Bennett DA, Wilson RS, Schneider JA, et al. Natural history of mild cognitive impairment in older persons. Neurology. 2002;59(2):198-205.
20. Breslow NE, Clayton DG. Approximate inference in generalized linear mixed models. J Am Stat Assoc. 1993;88(421):9-25. doi:10.1080/01621459.1993.10594284.
21. Laird NM, Ware JH. Random-effects models for longitudinal data. Biometrics. 1982;38(4):963-974.
22. Akaike H. Information Theory and an Extension of the Maximum Likelihood Principle. In: Parzen E, Tanabe K, Kitagawa G, eds. Selected Papers of Hirotugu Akaike. New York, NY: Springer; 1998:199- 213.
23. van Buuren S, Groothuis-Oudshoorn K. Mice: multivariate imputation by chained equations in R. J Stat Softw. 2011;45(3):1-67. doi:10.18637/jss.v045.i03.
24. Jonsson T, Atwal JK, Steinberg S, et al. A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. Nature. 2012;488(7409):96-99.
25. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease. Science. 2002;297(5580):353- 356.
26. Yu JT, Tan L, Hardy J. Apolipoprotein E in Alzheimer's disease. Annu Rev Neurosci. 2014;37: 79-100.
27. Mormino EC, Betensky RA, Hedden T, et al. Amyloid and APOE ϵ4 interact to influence short-term decline in preclinical Alzheimer disease. Neurology. 2014;82(20):1760-1767.
28. Kozauer N, Katz R. Regulatory innovation and drug development for early-stage Alzheimer's disease. N Engl J Med. 2013;368(13):1169-1171.
29. Alzheimer's Disease International.World Alzheimer Report 2009. http://www.alz.co.uk/research/files/WorldAlzheimerReport.pdf. Accessed May 11, 2017.